Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2019, Article ID 9109473, 23 pages
https://doi.org/10.1155/2019/9109473
Review Article

Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence?

1Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
2Department of Nephrology, Medical School, University of Ioannina, Ioannina, Greece

Correspondence should be addressed to Vassilios Liakopoulos; rg.teneto@lupokail

Received 16 October 2018; Revised 15 December 2018; Accepted 20 December 2018; Published 15 January 2019

Guest Editor: Mansur A. Sandhu

Copyright © 2019 Vassilios Liakopoulos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Pavlakou, V. Liakopoulos, T. Eleftheriadis, M. Mitsis, and E. Dounousi, “Oxidative stress and acute kidney injury in critical illness: pathophysiologic mechanisms-biomarkers-interventions, and future perspectives,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 6193694, 11 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Locatelli, B. Canaud, K. U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali, “Oxidative stress in end-stage renal disease: an emerging threat to patient outcome,” Nephrology Dialysis Transplantation, vol. 18, no. 7, pp. 1272–1280, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Sies, C. Berndt, and D. P. Jones, “Oxidative stress,” Annual Review of Biochemistry, vol. 86, no. 1, pp. 715–748, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Galli, M. Piroddi, C. Annetti, C. Aisa, E. Floridi, and A. Floridi, “Oxidative stress and reactive oxygen species,” Contributions to Nephrology, vol. 149, pp. 240–260, 2005. View at Publisher · View at Google Scholar
  5. S. Roumeliotis, A. Roumeliotis, S. Panagoutsos et al., “Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy,” Journal of Diabetes and its Complications, vol. 31, no. 10, pp. 1527–1532, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Hasselwander and I. S. Young, “Oxidative stress in chronic renal failure,” Free Radical Research, vol. 29, no. 1, pp. 1–11, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Annuk, M. Zilmer, L. Lind, T. Linde, and B. Fellstrom, “Oxidative stress and endothelial function in chronic renal failure,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2747–2752, 2001. View at Google Scholar
  8. E. Dounousi, E. Papavasiliou, A. Makedou et al., “Oxidative stress is progressively enhanced with advancing stages of CKD,” American Journal of Kidney Diseases, vol. 48, no. 5, pp. 752–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Liakopoulos, S. Roumeliotis, X. Gorny, E. Dounousi, and P. R. Mertens, “Oxidative stress in hemodialysis patients: a review of the literature,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 3081856, 22 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Ferraro, F. Galli, B. Frei et al., “Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients,” Kidney International, vol. 63, no. 6, pp. 2207–2213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Liakopoulos, S. Roumeliotis, X. Gorny, T. Eleftheriadis, and P. R. Mertens, “Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 3494867, 14 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Liakopoulos, S. Roumeliotis, S. Zarogiannis, T. Eleftheriadis, and P. R. Mertens, “Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions,” Seminars in Dialysis, vol. 32, no. 1, pp. 58–71, 2018. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Modaresi, M. Nafar, and Z. Sahraei, “Oxidative stress in chronic kidney disease,” Iranian Journal of Kidney Disease, vol. 9, no. 3, pp. 165–179, 2015. View at Google Scholar
  14. G. J. Handelman, M. F. Walter, R. Adhikarla et al., “Elevated plasma F2-isoprostanes in patients on long-term hemodialysis,” Kidney International, vol. 59, no. 5, pp. 1960–1966, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. A. T. Nguyen, C. Lethias, J. Zingraff, A. Herbelin, C. Naret, and B. Descamps-Latscha, “Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood,” Kidney International, vol. 28, no. 2, pp. 158–167, 1985. View at Publisher · View at Google Scholar · View at Scopus
  16. M. F. Chen, C. L. Chang, and S. Y. Liou, “Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis,” Blood Purification, vol. 16, no. 5, pp. 290–300, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. C. C. Yang, S. P. Hsu, M. S. Wu, S. M. Hsu, and C. T. Chien, “Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress,” Kidney International, vol. 69, no. 4, pp. 706–714, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Canaud, J. P. Cristol, M. Morena, H. Leray-Moragues, J. Y. Bosc, and F. Vaussenat, “Imbalance of oxidants and antioxidants in haemodialysis patients,” Blood Purification, vol. 17, no. 2-3, pp. 99–106, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Bayes, M. C. Pastor, J. Bonal, J. Junca, and R. Romero, “Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E,” Nephrology Dialysis Transplantation, vol. 16, no. 11, pp. 2172–2175, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Morena, J. P. Cristol, J. Y. Bosc et al., “Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 17, no. 3, pp. 422–427, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Clermont, S. Lecour, J. F. Cabanne et al., “Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients,” Free Radical Biology & Medicine, vol. 31, no. 2, pp. 233–241, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Galli, A. Azzi, M. Birringer et al., “Vitamin E: emerging aspects and new directions,” Free Radical Biology & Medicine, vol. 102, pp. 16–36, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Giusepponi, P. Torquato, D. Bartolini et al., “Determination of tocopherols and their metabolites by liquid-chromatography coupled with tandem mass spectrometry in human plasma and serum,” Talanta, vol. 170, pp. 552–561, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Schubert, S. Kluge, L. Schmölz et al., “Long-chain metabolites of vitamin E: metabolic activation as a general concept for lipid-soluble vitamins?” Antioxidants, vol. 7, no. 1, p. 10, 2018. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Galli, A. G. Floridi, A. Floridi, and U. Buoncristiani, “Accumulation of vitamin E metabolites in the blood of renal failure patients,” Clinical Nutrition, vol. 23, no. 2, pp. 205–212, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Galli, U. Buoncristiani, C. Conte, C. Aisa, and A. Floridi, “Vitamin E in uremia and dialysis patients,” Annals of the New York Academy of Sciences, vol. 1031, no. 1, pp. 348–351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Himmelfarb, J. Kane, E. Mcmonagle et al., “Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease,” Kidney International, vol. 64, no. 3, pp. 978–991, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Maccarrone, M. Taccone-Gallucci, C. Meloni et al., “Activation of 5-lipoxygenase and related cell membrane lipoperoxidation in hemodialysis patients,” Journal of the American Society of Nephrology, vol. 10, no. 9, pp. 1991–1996, 1999. View at Google Scholar
  29. E. B. Rimm, M. J. Stampfer, A. Ascherio, E. Giovannucci, G. A. Colditz, and W. C. Willett, “Vitamin E consumption and the risk of coronary heart disease in men,” The New England Journal of Medicine, vol. 328, no. 20, pp. 1450–1456, 1993. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Stampfer, C. H. Hennekens, J. A. E. Manson, G. A. Colditz, B. Rosner, and W. C. Willett, “Vitamin E consumption and the risk of coronary disease in women,” The New England Journal of Medicine, vol. 328, no. 20, pp. 1444–1449, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Lubrano, M. Taccone-Gallucci, A. Piazza et al., “Vitamin E supplementation and oxidative status of peripheral blood mononuclear cells and lymphocyte subsets in hemodialysis patients,” Nutrition, vol. 8, no. 2, pp. 94–97, 1992. View at Google Scholar
  32. M. Taccone-Gallucci, O. Giardini, C. Ausiello et al., “Vitamin E supplementation in hemodialysis patients: effects on peripheral blood mononuclear cells lipid peroxidation and immune response,” Clinical Nephrology, vol. 25, no. 2, pp. 81–86, 1986. View at Google Scholar
  33. M. Hodkova, S. Dusilova-Sulkova, A. Skalicka, M. Kalousova, T. Zima, and J. Bartunkova, “Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients,” Renal Failure, vol. 27, no. 2, pp. 135–141, 2005. View at Publisher · View at Google Scholar
  34. K. Wieczorowska-Tobis, A. Breborowicz, J. Witowski, L. Martis, and D. G. Oreopoulos, “Effect of vitamin E on peroxidation and permeability of the peritoneum,” Journal of Physiology and Pharmacology, vol. 47, no. 3, pp. 535–543, 1996. View at Google Scholar
  35. M. Taccone-Gallucci, R. Lubrano, V. Mazzarella et al., “Red blood cell membrane lipid peroxidation and chronic haemolysis in haemodialysis patients,” Life Support Systems, vol. 3, Supplement 1, pp. 41–44, 1985. View at Google Scholar
  36. M. Taccone-Gallucci, O. Giardini, R. Lubrano et al., “Red blood cell membrane lipid peroxidation in continuous ambulatory peritoneal dialysis patients,” American Journal of Nephrology, vol. 6, no. 2, pp. 92–95, 1986. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Giardini, M. Taccone-Gallucci, R. Lubrano et al., “Effects of alpha-tocopherol administration on red blood cell membrane lipid peroxidation in hemodialysis patients,” Clinical Nephrology, vol. 21, no. 3, pp. 174–177, 1984. View at Google Scholar
  38. R. Lubrano, M. Taccone-Gallucci, V. Mazzarella et al., “Relationship between red blood cell lipid peroxidation, plasma hemoglobin, and red blood cell osmotic resistance before and after vitamin E supplementation in hemodialysis patients,” Artificial Organs, vol. 10, no. 3, pp. 245–248, 1986. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Ono, “Effects of large dose vitamin E supplementation on anemia in hemodialysis patients,” Nephron, vol. 40, no. 4, pp. 440–445, 1985. View at Publisher · View at Google Scholar
  40. J. P. Cristol, J. Y. Bosc, S. Badiou et al., “Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation,” Nephrology Dialysis Transplantation, vol. 12, no. 11, pp. 2312–2317, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Nemeth, S. Turi, I. Haszon, and C. Bereczki, “Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis,” Pediatric Nephrology, vol. 14, no. 1, pp. 13–17, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. J. M. Roob, G. Khoschsorur, A. Tiran, J. H. Horina, H. Holzer, and B. M. Winklhofer-Roob, “Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 539–549, 2000. View at Google Scholar
  43. K. S. Smith, C. L. Lee, J. W. Ridlington, S. W. Leonard, S. Devaraj, and M. G. Traber, “Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients,” Lipids, vol. 38, no. 8, pp. 813–819, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Sinsakul, J. R. Drake, J. N. Leavitt Jr., B. R. Harrison, and C. D. Fitch, “Lack of effect of vitamin E therapy on the anemia of patients receiving hemodialysis,” The American Journal of Clinical Nutrition, vol. 39, no. 2, pp. 223–226, 1984. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Lillo-Ferez, B. Allain, C. Dupommereulle, P. Prieur, and M. Petrover, “Inefficacy of vitamin E supplementation on anemia in hemodialysis patients,” Nephron, vol. 45, no. 1, pp. 79-80, 1987. View at Publisher · View at Google Scholar
  46. A. Aguilera, J. L. Teruel, J. J. Villatruela, M. Rivera, and J. Ortuno, “Effect of vitamin E administration on erythropoietin values and anaemia in hemodialysis patients,” Nephrology Dialysis Transplantation, vol. 8, no. 4, p. 379, 1993. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. Upston, A. C. Terentis, and R. Stocker, “Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement,” The FASEB Journal, vol. 13, no. 9, pp. 977–994, 1999. View at Publisher · View at Google Scholar
  48. L. Lu, P. Erhard, R. G. Salomon, and M. F. Weiss, “Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial,” American Journal of Kidney Diseases, vol. 50, no. 2, pp. 305–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. K. N. Islam, D. O’Byrne, S. Devaraj, B. Palmer, S. M. Grundy, and I. Jialal, “Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy,” Atherosclerosis, vol. 150, no. 1, pp. 217–224, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Giray, E. Kan, M. Bali, F. Hincal, and N. Basaran, “The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients,” Clinica Chimica Acta, vol. 338, no. 1-2, pp. 91–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Inal, G. Kanbak, S. Sen, F. Akyuz, and E. Sunal, “Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy,” Free Radical Research, vol. 31, no. 3, pp. 211–216, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Galli, Z. Varga, J. Balla et al., “Vitamin E, lipid profile, and peroxidation in hemodialysis patients,” Kidney International, vol. 59, pp. S148–S154, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. F. A. Domenici, M. T. I. Vannucchi, A. A. Jordão Jr, M. S. S. Meirelles, and H. Vannucchi, “DNA oxidative damage in patients with dialysis treatment,” Renal Failure, vol. 27, no. 6, pp. 689–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Uzum, O. Toprak, M. K. Gumustas, S. Ciftci, and S. Sen, “Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis,” Journal of Nephrology, vol. 19, no. 6, pp. 739–745, 2006. View at Google Scholar
  55. G. Boudouris, I. I. Verginadis, Y. V. Simos et al., “Oxidative stress in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and the significant role of vitamin C and E supplementation,” International Urology and Nephrology, vol. 45, no. 4, pp. 1137–1144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Badiou, J. P. Cristol, M. Morena et al., “Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients,” International Journal for Vitamin and Nutrition Research, vol. 73, no. 4, pp. 290–296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. B. H. Khor, S. S. Narayanan, S. Sahathevan et al., “Efficacy of nutritional interventions on inflammatory markers in haemodialysis patients: a systematic review and limited meta-analysis,” Nutrients, vol. 10, no. 4, 2018. View at Publisher · View at Google Scholar · View at Scopus
  58. S. H. A. Diepeveen, G. W. H. E. Verhoeven, J. van der Palen et al., “Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial,” Journal of Internal Medicine, vol. 257, no. 5, pp. 438–445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Kamgar, F. Zaldivar, N. D. Vaziri, and M. V. Pahl, “Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease,” Journal of the National Medical Association, vol. 101, no. 4, pp. 336–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. D. O'Byrne, S. Devaraj, K. N. Islam et al., “Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy,” Metabolism, vol. 50, no. 2, pp. 207–215, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Sanaka, C. Takahashi, M. Sanaka et al., “Accumulation of phosphatydilcholine-hydroperoxide in dialysis patients with diabetic nephropathy,” Clinical Nephrology, vol. 44, Supplement 1, pp. S33–S37, 1995. View at Google Scholar
  62. G. Antoniadi, T. Eleftheriadis, V. Liakopoulos et al., “Effect of one-year oral alpha-tocopherol administration on the antioxidant defense system in hemodialysis patients,” Therapeutic Apheresis and Dialysis, vol. 12, no. 3, pp. 237–242, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. J. S. Coombes and R. G. Fassett, “Antioxidant therapy in hemodialysis patients: a systematic review,” Kidney International, vol. 81, no. 3, pp. 233–246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Boaz, S. Smetana, T. Weinstein et al., “Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial,” The Lancet, vol. 356, no. 9237, pp. 1213–1218, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. E. R. Miller III, R. Pastor-Barriuso, D. Dalal, R. A. Riemersma, L. J. Appel, and E. Guallar, “Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality,” Annals of Internal Medicine, vol. 142, no. 1, pp. 37–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Mune, S. Yukawa, M. Kishino et al., “Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients,” Kidney International, vol. 56, Supplement 71, pp. S126–S129, 1999. View at Publisher · View at Google Scholar
  67. M. Usberti, G. Gerardi, G. Bufano et al., “Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients,” American Journal of Kidney Diseases, vol. 40, no. 3, pp. 590–599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. A.-S. Bargnoux, J.-P. Cristol, I. Jaussent et al., “Vitamin E-coated polysulfone membrane improved red blood cell antioxidant status in hemodialysis patients,” Journal of Nephrology, vol. 26, no. 3, pp. 556–563, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Locatelli, S. Andrulli, S. M. Viganò et al., “Evaluation of the impact of a new synthetic vitamin E-bonded membrane on the hypo-responsiveness to the erythropoietin therapy in hemodialysis patients: a multicenter study,” Blood Purification, vol. 43, no. 4, pp. 338–345, 2017. View at Publisher · View at Google Scholar · View at Scopus
  70. M. A. Sosa, E. M. Balk, J. Lau et al., “A systematic review of the effect of the Excebrane dialyser on biomarkers of lipid peroxidation,” Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2825–2833, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. S. K. Yang, L. Xiao, B. Xu, X. X. Xu, F. Y. Liu, and L. Sun, “Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis,” Renal Failure, vol. 36, no. 5, pp. 722–731, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. G. D'Arrigo, R. Baggetta, G. Tripepi, F. Galli, and D. Bolignano, “Effects of vitamin E-coated versus conventional membranes in chronic hemodialysis patients: a systematic review and meta-analysis,” Blood Purification, vol. 43, no. 1-3, pp. 101–122, 2017. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Piroddi, F. Pilolli, M. Aritomi, and F. Galli, “Vitamin E as a functional and biocompatibility modifier of synthetic hemodialyzer membranes: an overview of the literature on vitamin E-modified hemodialyzer membranes,” American Journal of Nephrology, vol. 35, no. 6, pp. 559–572, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Abdollahzad, S. Eghtesadi, I. Nourmohammadi, M. Khadem-Ansari, H. Nejad-Gashti, and A. Esmaillzadeh, “Effect of vitamin C supplementation on oxidative stress and lipid profiles in hemodialysis patients,” International Journal for Vitamin and Nutrition Research, vol. 79, no. 56, pp. 281–287, 2009. View at Publisher · View at Google Scholar
  75. F. Candan, F. Gultekin, and F. Candan, “Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc-deficient haemodialysis patients,” Cell Biochemistry and Function, vol. 20, no. 2, pp. 95–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Ghiadoni, A. Cupisti, Y. Huang et al., “Endothelial dysfunction and oxidative stress in chronic renal failure,” Journal of Nephrology, vol. 17, no. 4, pp. 512–519, 2004. View at Google Scholar
  77. M. Sato, Y. Matsumoto, H. Morita, H. Takemura, K. Shimoi, and I. Amano, “Effects of vitamin supplementation on microcirculatory disturbance in hemodialysis patients without peripheral arterial disease,” Clinical Nephrology, vol. 60, no. 07, pp. 28–34, 2003. View at Publisher · View at Google Scholar
  78. X.-F. Shi, “Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients,” Renal Failure, vol. 27, no. 2, pp. 213–219, 2005. View at Publisher · View at Google Scholar
  79. G. Ferretti, T. Bacchetti, S. Masciangelo, and G. Pallotta, “Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation,” Clinical Biochemistry, vol. 41, no. 6, pp. 381–386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. D.-C. Tarng, T.-Y. Liu, and T.-P. Huang, “Protective effect of vitamin C on 8-hydroxy-2-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients,” Kidney International, vol. 66, no. 2, pp. 820–831, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Chan, A. Irish, K. D. Croft, and G. Dogra, “Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients,” Nephrology, Dialysis, Transplantation, vol. 21, no. 1, pp. 234-235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Washio, M. Inagaki, M. Tsuji et al., “Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker,” Nephron Clinical Practice, vol. 109, no. 2, pp. c49–c54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Ramos and A. Martinez-Castelao, “Lipoperoxidation and hemodialysis,” Metabolism, vol. 57, no. 10, pp. 1369–1374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Fumeron, T. Nguyen-Khoa, C. Saltiel et al., “Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients,” Nephrology, Dialysis, Transplantation, vol. 20, no. 9, pp. 1874–1879, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. A. S. De Vriese, D. Borrey, E. Mahieu et al., “Oral vitamin C administration increases lipid peroxidation in hemodialysis patients,” Nephron Clinical Practice, vol. 108, no. 1, pp. c28–c34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Eiselt, J. Racek, K. Opatrny Jr., L. Trefil, and P. Stehlik, “The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C,” Blood Purification, vol. 24, no. 5-6, pp. 531–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Tsapas, I. Magoula, K. Paletas, and L. Concouris, “Effect of peritoneal dialysis on plasma levels of ascorbic acid,” Nephron, vol. 33, no. 1, pp. 34–37, 1983. View at Publisher · View at Google Scholar
  88. I. Sundl, J. M. Roob, A. Meinitzer et al., “Antioxidant status of patients on peritoneal dialysis: associations with inflammation and glycoxidative stress,” Peritoneal Dialysis International, vol. 29, no. 1, pp. 89–101, 2009. View at Google Scholar
  89. K. Zhang, L. Liu, X. Cheng, J. Dong, Q. Geng, and L. Zuo, “Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein,” BMC Nephrology, vol. 12, no. 1, p. 18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. F. O. Finkelstein, P. Juergensen, S. Wang et al., “Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis,” Peritoneal Dialysis International, vol. 31, no. 1, pp. 74–79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. A. G. Bostom, M. A. Carpenter, J. W. Kusek et al., “Rationale and design of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial,” American Heart Journal, vol. 152, no. 3, pp. 448.e1–448.e7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. P. W. Nanayakkara, C. van Guldener, P. M. ter Wee et al., “Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study,” Archives of Internal Medicine, vol. 167, no. 12, pp. 1262–1270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Stopper, A. T. Treutlein, U. Bahner et al., “Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation,” Nephrology, Dialysis, Transplantation, vol. 23, no. 10, pp. 3272–3279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. N. L. Alderson, M. E. Chachich, N. N. Youssef et al., “The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats,” Kidney International, vol. 63, no. 6, pp. 2123–2133, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. T. O. Metz, N. L. Alderson, S. R. Thorpe, and J. W. Baynes, “Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications,” Archives of Biochemistry and Biophysics, vol. 419, no. 1, pp. 41–49, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. T. O. Metz, N. L. Alderson, M. E. Chachich, S. R. Thorpe, and J. W. Baynes, “Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications,” Journal of Biological Chemistry, vol. 278, no. 43, pp. 42012–42019, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Zheng, Y. J. Zeng, A. R. Plati et al., “Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice,” Kidney International, vol. 70, no. 3, pp. 507–514, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. M. E. Williams, W. K. Bolton, R. G. Khalifah, T. P. Degenhardt, R. J. Schotzinger, and J. B. McGill, “Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy,” American Journal of Nephrology, vol. 27, no. 6, pp. 605–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Apeland, M. A. Mansoor, I. Seljeflot, I. Bronstad, L. Goransson, and R. E. Strandjord, “Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy,” Journal of Internal Medicine, vol. 252, no. 5, pp. 456–464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. V. D. A. Delfino, A. C. de Andrade Vianna, A. J. Mocelin, D. S. Barbosa, R. A. Mise, and T. Matsuo, “Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients,” Nutrition, vol. 23, no. 3, pp. 242–247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. M. M. Nascimento, M. E. Suliman, Y. Murayama et al., “Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study,” Journal of Renal Nutrition, vol. 16, no. 2, pp. 119–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. S. U. Nigwekar, A. Kang, S. Zoungas et al., “Interventions for lowering plasma homocysteine levels in dialysis patients,” Cochrane Database of Systematic Reviews, vol. 31, no. 5, 2016. View at Publisher · View at Google Scholar · View at Scopus
  103. C. C. Wu, J. H. Chang, C. C. Chen et al., “Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism,” The Tohoku Journal of Experimental Medicine, vol. 223, no. 3, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Tanaka, K. Tokunaga, H. Komaba et al., “Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism,” Therapeutic Apheresis and Dialysis, vol. 15, no. 2, pp. 161–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. M. J. Izquierdo, M. Cavia, P. Muñiz et al., “Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients,” BMC Nephrology, vol. 13, no. 1, p. 159, 2012. View at Publisher · View at Google Scholar
  106. M. R. Tamadon, A. Soleimani, F. Keneshlou et al., “Clinical trial on the effects of vitamin D supplementation on metabolic profiles in diabetic hemodialysis,” Hormone and Metabolic Research, vol. 50, no. 01, pp. 50–55, 2018. View at Publisher · View at Google Scholar · View at Scopus
  107. L. Yang, L. Wu, S. Du, Y. Hu, Y. Fan, and J. Ma, “1,25(OH)2D3 inhibits high glucose-induced apoptosis and ROS production in human peritoneal mesothelial cells via the MAPK/P38 pathway,” Molecular Medicine Reports, vol. 14, no. 1, pp. 839–844, 2016. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Yang, Y. Fan, X. Zhang, J. Liu, and J. Ma, “Effect of 1,25(OH)2D3 on high glucose-induced autophagy inhibition in peritoneum,” Molecular Medicine Reports, vol. 16, no. 5, pp. 7080–7085, 2017. View at Publisher · View at Google Scholar · View at Scopus
  109. L. Yang, Y. Fan, X. Zhang, W. Huang, and J. Ma, “1,25(OH)2D3 treatment attenuates high glucose-induced peritoneal epithelial to mesenchymal transition in mice,” Molecular Medicine Reports, vol. 16, no. 4, pp. 3817–3824, 2017. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Lass, M. J. Forster, and R. S. Sohal, “Effects of coenzyme Q10 and α-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial α-tocopherol by coenzyme Q10,” Free Radical Biology & Medicine, vol. 26, no. 11-12, pp. 1375–1382, 1999. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Morotomi, H. Oniki, K. Onoyama, K. Fukiyama, and T. Omae, “Effects of coenzyme Q10 on the blood pressure and renal renin content in spontaneously hypertensive rats,” Igaku Kenkyu, vol. 45, no. 5, pp. 303–308, 1975. View at Google Scholar
  112. T. Igarashi, Y. Nakajima, M. Tanaka, and S. Otake, “Effect of coenzyme Q10 on experimental hypertension in rats and dogs,” The Journal of Pharmacology and Experimental Therapeutics, vol. 189, no. 1, pp. 149–156, 1974. View at Google Scholar
  113. F. M. Rauscher, R. A. Sanders, and J. B. Watkins, “Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats,” Journal of Biochemical and Molecular Toxicology, vol. 15, no. 1, pp. 41–46, 2001. View at Publisher · View at Google Scholar
  114. M. Farswan, S. Rathod, A. Upaganlawar, and A. Semwal, “Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats,” Indian Journal of Experimental Biology, vol. 43, no. 10, pp. 845–848, 2005. View at Google Scholar
  115. A. Upaganlawar, M. Farswan, S. Rathod, and R. Balaraman, “Modification of biochemical parameters of gentamicin nephrotoxicity by coenzyme Q10 and green tea in rats,” Indian Journal of Experimental Biology, vol. 44, no. 5, pp. 416–418, 2006. View at Google Scholar
  116. T. Sakata, R. Furuya, T. Shimazu, M. Odamaki, S. Ohkawa, and H. Kumagai, “Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients,” Blood Purification, vol. 26, no. 4, pp. 371–378, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. C. K. Yeung, F. T. Billings, A. J. Claessens et al., “Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress,” BMC Nephrology, vol. 16, no. 1, p. 183, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. H. Gokbel, S. Turk, N. Okudan et al., “Effects of coenzyme Q10 supplementation on exercise performance and markers of oxidative stress in hemodialysis patients: a double-blind placebo-controlled crossover trial,” American Journal of Therapeutics, vol. 23, no. 6, pp. e1736–e1743, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. M. B. Rivara, C. K. Yeung, C. Robinson-Cohen et al., “Effect of coenzyme Q10 on biomarkers of oxidative stress and cardiac function in hemodialysis patients: the CoQ10 biomarker trial,” American Journal of Kidney Diseases, vol. 69, no. 3, pp. 389–399, 2017. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Matera, G. Bellinghieri, G. Costantino, D. Santoro, M. Calvani, and V. Savica, “History of L-carnitine: implications for renal disease,” Journal of Renal Nutrition, vol. 13, no. 1, pp. 2–14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. R. S. Sloan, B. Kastan, S. I. Rice et al., “Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation,” American Journal of Kidney Diseases, vol. 32, no. 2, pp. 265–272, 1998. View at Publisher · View at Google Scholar · View at Scopus
  122. E. P. Brass, S. Adler, K. E. Sietsema et al., “Intravenous l-carnitine increases plasma carnitine, reducesfatigue, and may preserve exercise capacity in hemodialysis patients,” American Journal of Kidney Diseases, vol. 37, no. 5, pp. 1018–1028, 2001. View at Publisher · View at Google Scholar · View at Scopus
  123. J. M. Hurot, M. Cucherat, M. Haugh, and D. Fouque, “Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review,” Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 708–714, 2002. View at Google Scholar
  124. Y. Chen, M. Abbate, L. Tang et al., “L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis,” The American Journal of Clinical Nutrition, vol. 99, no. 2, pp. 408–422, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. S. K. Yang, L. Xiao, P. A. Song, X. Xu, F. Y. Liu, and L. Sun, “Effect of L-carnitine therapy on patients in maintenance hemodialysis: a systematic review and meta-analysis,” Journal of Nephrology, vol. 27, no. 3, pp. 317–329, 2014. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Friedman and S. Moe, “Review of the effects of omega-3 supplementation in dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 2, pp. 182–192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. J. M. Peake, G. C. Gobe, R. G. Fassett, and J. S. Coombes, “The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats,” Molecular Nutrition & Food Research, vol. 55, no. 3, pp. 400–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. A. M. Hung, C. Booker, C. D. Ellis et al., “Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients,” Nephrology, Dialysis, Transplantation, vol. 30, no. 2, pp. 266–274, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Tayyebi-Khosroshahi, J. Houshyar, A. Tabrizi, A.-M. Vatankhah, N. R. Zonouz, and R. Dehghan-Hesari, “Effect of omega-3 fatty acid on oxidative stress in patients on hemodialysis,” Iranian Journal of Kidney Diseases, vol. 4, no. 4, pp. 322–326, 2010. View at Google Scholar
  130. M. Ando, T. Sanaka, and H. Nihei, “Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients,” Journal of the American Society of Nephrology, vol. 10, no. 10, pp. 2177–2184, 1999. View at Google Scholar
  131. A. M. de Mattos, J. A. C. da Costa, A. A. Jordão Júnior, and P. G. Chiarello, “Omega-3 fatty acid supplementation is associated with oxidative stress and dyslipidemia, but does not contribute to better lipid and oxidative status on hemodialysis patients,” Journal of Renal Nutrition, vol. 27, no. 5, pp. 333–339, 2017. View at Publisher · View at Google Scholar · View at Scopus
  132. Z. A. Daud, B. Tubie, J. Adams et al., “Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients,” Vascular Health and Risk Management, vol. 8, pp. 187–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. G. B. Perunicic-Pekovic, Z. R. Rasic, S. I. Pljesa et al., “Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients,” Nephrology, vol. 12, no. 4, pp. 331–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Taheri, N. Keyvandarian, F. Moeinzadeh, M. Mortazavi, and A. E. Naini, “The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients,” Advanced Biomedical Research, vol. 3, no. 1, p. 142, 2014. View at Publisher · View at Google Scholar
  135. A. E. Naini, R. E. Asiabi, N. Keivandarian, and F. Moeinzadeh, “Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis,” Advanced Biomedical Research, vol. 4, no. 1, p. 167, 2015. View at Publisher · View at Google Scholar
  136. A. E. Naini, N. Keyvandarian, M. Mortazavi, S. Taheri, and S. M. Hosseini, “Effect of omega-3 fatty acids on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patients,” Journal of Research in Pharmacy Practice, vol. 4, no. 3, pp. 135–141, 2015. View at Publisher · View at Google Scholar
  137. A. S. Abdelhamid, T. J. Brown, J. S. Brainard et al., “Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease,” Cochrane Database of Systematic Reviews, vol. 7, article CD003177, 2018. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Aung, J. Halsey, D. Kromhout et al., “Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals,” JAMA Cardiology, vol. 3, no. 3, pp. 225–234, 2018. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Taccone-Gallucci, A. Noce, P. Bertucci et al., “Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients,” Journal of Trace Elements in Medicine and Biology, vol. 24, no. 1, pp. 27–30, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. O. Nishikawa, M. Mune, M. Miyano et al., “Effect of simvastatin on the lipid profile of hemodialysis patients,” Kidney International, vol. 71, pp. S219–S221, 1999. View at Google Scholar
  141. N. Kishimoto, T. Hayashi, I. Sakuma et al., “A hydroxymethylglutaryl coenzyme a reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis,” International Journal of Cardiology, vol. 145, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. S. D. Navaneethan, S. U. Nigwekar, V. Perkovic, D. W. Johnson, J. C. Craig, and G. F. Strippoli, “HMG CoA reductase inhibitors (statins) for dialysis patients,” Cochrane Database of Systematic Reviews, vol. 8, no. 3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. J. Deng, Q. Wu, Y. Liao, D. Huo, and Z. Yang, “Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis,” Nephrology, vol. 17, no. 6, pp. 545–551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. H. Sigel, B. Prijs, D. B. McCormick, and J. C. H. Shih, “Stability and structure of binary and ternary complexes of α-lipoate and lipoate derivatives with Mn2+, Cu2+, and Zn2+ in solution,” Archives of Biochemistry and Biophysics, vol. 187, no. 1, pp. 208–214, 1978. View at Publisher · View at Google Scholar · View at Scopus
  145. J. Liu, “The effects and mechanisms of mitochondrial nutrient α-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview,” Neurochemical Research, vol. 33, no. 1, pp. 194–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. K. Petersen Shay, R. F. Moreau, E. J. Smith, and T. M. Hagen, “Is α-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity,” IUBMB Life, vol. 60, no. 6, pp. 362–367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. H. Kim, H. J. Kim, K. Lee et al., “α-Lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway,” Journal of Cellular and Molecular Medicine, vol. 16, no. 2, pp. 273–286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  148. M. Takaoka, M. Ohkita, Y. Kobayashi, M. Yuba, and Y. Matsumura, “Protective effect of α-LIPOIC acid against ischaemic acute renal failure in rats,” Clinical and Experimental Pharmacology and Physiology, vol. 29, no. 3, pp. 189–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. Ö. Şehirli, E. Şener, Ş. Çetinel, M. Yüksel, N. Gedik, and G. Şener, “α-Lipoic acid protects against renal ischaemia–reperfusion injury in rats,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 3, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  150. L. Wang, C.-G. Wu, C.-Q. Fang et al., “The protective effect of α-lipoic acid on mitochondria in the kidney of diabetic rats,” International Journal of Clinical and Experimental Medicine, vol. 6, no. 2, pp. 90–97, 2013. View at Google Scholar
  151. M. F. Melhem, P. A. Craven, J. Liachenko, and F. R. DeRubertis, “α-Lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes,” Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 108–116, 2002. View at Google Scholar
  152. F. Bhatti, R. W. Mankhey, L. Asico, M. T. Quinn, W. J. Welch, and C. Maric, “Mechanisms of antioxidant and pro-oxidant effects of α-lipoic acid in the diabetic and nondiabetic kidney,” Kidney International, vol. 67, no. 4, pp. 1371–1380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  153. K. P. Malarkodi, A. V. Balachandar, and P. Varalakshmi, “Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney,” Molecular and Cellular Biochemistry, vol. 247, no. 1/2, pp. 9–13, 2003. View at Publisher · View at Google Scholar · View at Scopus
  154. D. P. Malarkodi, A. V. Balachandar, and P. Varalakshmi, “The influence of lipoic acid on adriamycin induced nephrotoxicity in rats,” Molecular and Cellular Biochemistry, vol. 247, no. 1/2, pp. 15–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  155. G. Amudha, A. Josephine, Y. Mythili, R. Sundarapandiyan, and P. Varalakshmi, “Therapeutic efficacy of dl-α-lipoic acid on cyclosporine A induced renal alterations,” European Journal of Pharmacology, vol. 571, no. 2-3, pp. 209–214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. G. Amudha, A. Josephine, and P. Varalakshmi, “Role of lipoic acid in reducing the oxidative stress induced by cyclosporine A,” Clinica Chimica Acta, vol. 372, no. 1-2, pp. 134–139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  157. A. O. Abdel-Zaher, R. H. Abdel-Hady, M. M. Mahmoud, and M. M. Y. Farrag, “The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage,” Toxicology, vol. 243, no. 3, pp. 261–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. T. Khabbazi, R. Mahdavi, J. Safa, and P. Pour-Abdollahi, “Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis,” Journal of Renal Nutrition, vol. 22, no. 2, pp. 244–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. J. Safa, M. R. Ardalan, M. Rezazadehsaatlou, M. Mesgari, R. Mahdavi, and M. P. Jadid, “Effects of alpha lipoic acid supplementation on serum levels of IL-8 and TNF-α in patient with ESRD undergoing hemodialysis,” International Urology and Nephrology, vol. 46, no. 8, pp. 1633–1638, 2014. View at Publisher · View at Google Scholar · View at Scopus
  160. J. W. Chang, E. K. Lee, T. H. Kim et al., “Effects of α-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study,” American Journal of Nephrology, vol. 27, no. 1, pp. 70–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. G. A. El-Nakib, T. M. Mostafa, T. M. Abbas, M. M. El-Shishtawy, M. M. Mabrouk, and M. A. Sobh, “Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis,” International Journal of Nephrology and Renovascular Disease, vol. 6, pp. 161–168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. A. Ahmadi, N. Mazooji, J. Roozbeh, Z. Mazloom, and J. Hasanzade, “Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients,” Iranian Journal of Kidney Diseases, vol. 7, no. 6, pp. 461–467, 2013. View at Google Scholar
  163. J. Himmelfarb, T. A. Ikizler, C. Ellis et al., “Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial,” Journal of the American Society of Nephrology, vol. 25, no. 3, pp. 623–633, 2014. View at Publisher · View at Google Scholar · View at Scopus
  164. Y. Fujishima, M. Ohsawa, K. Itai et al., “Serum selenium levels are inversely associated with death risk among hemodialysis patients,” Nephrology, Dialysis, Transplantation, vol. 26, no. 10, pp. 3331–3338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  165. M. Tonelli, N. Wiebe, A. Bello et al., “Concentrations of trace elements and clinical outcomes in hemodialysis patients: a prospective cohort study,” Clinical Journal of the American Society of Nephrology, vol. 13, no. 6, pp. 907–915, 2018. View at Publisher · View at Google Scholar · View at Scopus
  166. K. Kalantar-Zadeh and J. D. Kopple, “Trace elements and vitamins in maintenance dialysis patients,” Advances in Renal Replacement Therapy, vol. 10, no. 3, pp. 170–182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  167. T. Zima, O. Mestek, K. Němeček et al., “Trace elements in hemodialysis and continuous ambulatory peritoneal dialysis patients,” Blood Purification, vol. 16, no. 5, pp. 253–260, 1998. View at Publisher · View at Google Scholar · View at Scopus
  168. Y. Fujishima, M. Ohsawa, K. Itai et al., “Serum selenium levels in hemodialysis patients are significantly lower than those in healthy controls,” Blood Purification, vol. 32, no. 1, pp. 43–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. D. Rucker, R. Thadhani, and M. Tonelli, “Trace element status in hemodialysis patients,” Seminars in Dialysis, vol. 23, no. 4, pp. 389–395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. M. Pakfetrat, L. Malekmakan, and M. Hasheminasab, “Diminished selenium levels in hemodialysis and continuous ambulatory peritoneal dialysis patients,” Biological Trace Element Research, vol. 137, no. 3, pp. 335–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. M. Tonelli, N. Wiebe, B. Hemmelgarn et al., “Trace elements in hemodialysis patients: a systematic review and meta-analysis,” BMC Medicine, vol. 7, no. 1, p. 25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  172. A. A. Rashidi, M. Salehi, A. Piroozmand, and M. M. Sagheb, “Effects of zinc supplementation on serum zinc and C-reactive protein concentrations in hemodialysis patients,” Journal of Renal Nutrition, vol. 19, no. 6, pp. 475–478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  173. B. Rahimi-Ardabili, H. Argani, A. Ghorbanihaghjo et al., “Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients,” Renal Failure, vol. 34, no. 9, pp. 1123–1128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  174. M. Mazani, H. Argani, N. Rashtchizadeh et al., “Effects of zinc supplementation on antioxidant status and lipid peroxidation in hemodialysis patients,” Journal of Renal Nutrition, vol. 23, no. 3, pp. 180–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  175. C. H. Guo, P. C. Chen, G. S. Hsu, and C. L. Wang, “Zinc supplementation alters plasma aluminum and selenium status of patients undergoing dialysis: a pilot study,” Nutrients, vol. 5, no. 4, pp. 1456–1470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  176. L. J. Wang, M. Q. Wang, R. Hu et al., “Effect of zinc supplementation on maintenance hemodialysis patients: a systematic review and meta-analysis of 15 randomized controlled trials,” BioMed Research International, vol. 2017, Article ID 1024769, 11 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  177. B. A. Zachara, A. Adamowicz, U. Trafikowska, A. Trafikowska, J. Manitius, and E. Nartowicz, “Selenium and glutathione levels, and glutathione peroxidase activities in blood components of uremic patients on hemodialysis supplemented with selenium and treated with erythropoietin,” Journal of Trace Elements in Medicine and Biology, vol. 15, no. 4, pp. 201–208, 2001. View at Publisher · View at Google Scholar · View at Scopus
  178. B. A. Zachara, J. Gromadzinska, J. Palus et al., “The effect of selenium supplementation in the prevention of DNA damage in white blood cells of hemodialyzed patients: a pilot study,” Biological Trace Element Research, vol. 142, no. 3, pp. 274–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. M. Salehi, Z. Sohrabi, M. Ekramzadeh et al., “Selenium supplementation improves the nutritional status of hemodialysis patients: a randomized, double-blind, placebo-controlled trial,” Nephrology, Dialysis, Transplantation, vol. 28, no. 3, pp. 716–723, 2013. View at Publisher · View at Google Scholar · View at Scopus
  180. M. R. Ardalan, R. S. Tubbs, and M. M. Shoja, “Vitamin E and selenium co-supplementation attenuates oxidative stress in haemodialysis patients receiving intra-dialysis iron infusion,” Nephrology, Dialysis, Transplantation, vol. 22, no. 3, pp. 973–975, 2007. View at Publisher · View at Google Scholar · View at Scopus
  181. H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, “Curcumin: from ancient medicine to current clinical trials,” Cellular and Molecular Life Sciences, vol. 65, no. 11, pp. 1631–1652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  182. B. Joe and B. R. Lokesh, “Role of capsaicin, curcumin and dietary n—3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1224, no. 2, pp. 255–263, 1994. View at Publisher · View at Google Scholar · View at Scopus
  183. Sreejayan and M. N. A. Rao, “Curcuminoids as potent inhibitors of lipid peroxidation,” Journal of Pharmacy and Pharmacology, vol. 46, no. 12, pp. 1013–1016, 1994. View at Publisher · View at Google Scholar · View at Scopus
  184. D. Savitha, I. Mani, G. Ravikumar, and S. T. Avadhany, “Effect of curcumin in experimental peritonitis,” The Indian Journal of Surgery, vol. 77, no. 6, pp. 502–507, 2015. View at Publisher · View at Google Scholar · View at Scopus
  185. V. Soetikno, K. Watanabe, F. R. Sari et al., “Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats,” Molecular Nutrition & Food Research, vol. 55, no. 11, pp. 1655–1665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  186. V. Soetikno, F. R. Sari, P. T. Veeraveedu et al., “Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy,” Nutrition & Metabolism, vol. 8, no. 1, p. 35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  187. J. Chiu, Z. A. Khan, H. Farhangkhoee, and S. Chakrabarti, “Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-κB,” Nutrition, vol. 25, no. 9, pp. 964–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. M. Lu, N. Yin, W. Liu, X. Cui, S. Chen, and E. Wang, “Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling,” BioMed Research International, vol. 2017, Article ID 1516985, 10 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  189. S. S. Ghosh, H. D. Massey, R. Krieg et al., “Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation,” American Journal of Physiology-Renal Physiology, vol. 296, no. 5, pp. F1146–F1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  190. S. S. Ghosh, T. W. Gehr, and S. Ghosh, “Curcumin and chronic kidney disease (CKD): major mode of action through stimulating endogenous intestinal alkaline phosphatase,” Molecules, vol. 19, no. 12, pp. 20139–20156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  191. A. Jacob, L. Chaves, M. T. Eadon, A. Chang, R. J. Quigg, and J. J. Alexander, “Curcumin alleviates immune-complex-mediated glomerulonephritis in factor-H-deficient mice,” Immunology, vol. 139, no. 3, pp. 328–337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  192. E. Tapia, V. Soto, K. M. Ortiz-Vega et al., “Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 269039, 14 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  193. E. Tapia, Z. L. Zatarain-Barrón, R. Hernández-Pando et al., “Curcumin reverses glomerular hemodynamic alterations and oxidant stress in 5/6 nephrectomized rats,” Phytomedicine, vol. 20, no. 3-4, pp. 359–366, 2013. View at Publisher · View at Google Scholar · View at Scopus
  194. N. Venkatesan, D. Punithavathi, and V. Arumugam, “Curcumin prevents adriamycin nephrotoxicity in rats,” British Journal of Pharmacology, vol. 129, no. 2, pp. 231–234, 2000. View at Publisher · View at Google Scholar · View at Scopus
  195. O. Bayrak, E. Uz, R. Bayrak et al., “Curcumin protects against ischemia/reperfusion injury in rat kidneys,” World Journal of Urology, vol. 26, no. 3, pp. 285–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  196. V. Soetikno, F. R. Sari, A. P. Lakshmanan et al., “Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2–keap1 pathway,” Molecular Nutrition & Food Research, vol. 57, no. 9, pp. 1649–1659, 2013. View at Publisher · View at Google Scholar · View at Scopus
  197. A. Kuhad, S. Pilkhwal, S. Sharma, N. Tirkey, and K. Chopra, “Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity,” Journal of Agricultural and Food Chemistry, vol. 55, no. 25, pp. 10150–10155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  198. D. Shoskes, C. Lapierre, M. Cruz-Corerra et al., “Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial,” Transplantation, vol. 80, no. 11, pp. 1556–1559, 2005. View at Publisher · View at Google Scholar · View at Scopus
  199. M. Pakfetrat, M. Akmali, L. Malekmakan, M. Dabaghimanesh, and M. Khorsand, “Role of turmeric in oxidative modulation in end-stage renal disease patients,” Hemodialysis International, vol. 19, no. 1, pp. 124–131, 2015. View at Publisher · View at Google Scholar · View at Scopus
  200. A. A. Seddik, “The effect of turmeric and ginger on oxidative modulation in end stage renal disease (ESRD) patients,” International Journal, vol. 3, no. 11, pp. 657–670, 2015. View at Google Scholar
  201. M. Zahmatkesh and M. Tamadon, “Administration of turmeric (curcumin) in chronic renal failure; a narrative review on current knowledge,” Journal of Renal Endocrinology, vol. 2, article e06, 2016. View at Google Scholar
  202. L. Signorini, S. Granata, A. Lupo, and G. Zaza, “Naturally occurring compounds: new potential weapons against oxidative stress in chronic kidney disease,” International Journal of Molecular Sciences, vol. 18, no. 7, 2017. View at Publisher · View at Google Scholar · View at Scopus
  203. A. A. E. Bertelli, M. Migliori, V. Panichi et al., “Resveratrol, a component of wine and grapes, in the prevention of kidney disease,” Annals of the New York Academy of Sciences, vol. 957, no. 1, pp. 230–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  204. L. Giovannini, M. Migliori, B. M. Longoni et al., “Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys,” Journal of Cardiovascular Pharmacology, vol. 37, no. 3, pp. 262–270, 2001. View at Publisher · View at Google Scholar · View at Scopus
  205. M. Kolgazi, G. Şener, Ş. Çetinel, N. Gedik, and İ. Alican, “Resveratrol reduces renal and lung injury caused by sepsis in rats,” Journal of Surgical Research, vol. 134, no. 2, pp. 315–321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  206. S. Aydın, T. T. Şahin, M. Bacanlı et al., “Resveratrol protects sepsis-induced oxidative DNA damage in liver and kidney of rats,” Balkan Medical Journal, vol. 33, no. 6, pp. 594–601, 2016. View at Publisher · View at Google Scholar · View at Scopus
  207. C. Silan, Ö. Uzun, N. Ü. Çomunoglu, S. Gokçen, S. Bedirhan, and M. Cengiz, “Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol,” Biological and Pharmaceutical Bulletin, vol. 30, no. 1, pp. 79–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  208. C. L. Do Amaral, H. D. C. Francescato, T. M. Coimbra et al., “Resveratrol attenuates cisplatin-induced nephrotoxicity in rats,” Archives of Toxicology, vol. 82, no. 6, pp. 363–370, 2008. View at Publisher · View at Google Scholar · View at Scopus
  209. V. Chander, N. Tirkey, and K. Chopra, “Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism,” Toxicology, vol. 210, no. 1, pp. 55–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  210. S. Sharma, M. Anjaneyulu, S. K. Kulkarni, and K. Chopra, “Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats,” Pharmacology, vol. 76, no. 2, pp. 69–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  211. P. Castilla, A. Dávalos, J. L. Teruel et al., “Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients,” The American Journal of Clinical Nutrition, vol. 87, no. 4, pp. 1053–1061, 2008. View at Publisher · View at Google Scholar
  212. P. Castilla, R. Echarri, A. Dávalos et al., “Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects,” The American Journal of Clinical Nutrition, vol. 84, no. 1, pp. 252–262, 2006. View at Publisher · View at Google Scholar
  213. T. M. Spormann, F. W. Albert, T. Rath et al., “Anthocyanin/polyphenolic-rich fruit juice reduces oxidative cell damage in an intervention study with patients on hemodialysis,” Cancer Epidemiology, Biomarkers & Prevention, vol. 17, no. 12, pp. 3372–3380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  214. P. T. Wu, P. J. Fitschen, B. M. Kistler et al., “Effects of pomegranate extract supplementation on cardiovascular risk factors and physical function in hemodialysis patients,” Journal of Medicinal Food, vol. 18, no. 9, pp. 941–949, 2015. View at Publisher · View at Google Scholar · View at Scopus
  215. Z. Corredor, L. Rodríguez-Ribera, E. Coll et al., “Unfermented grape juice reduce genomic damage on patients undergoing hemodialysis,” Food and Chemical Toxicology, vol. 92, pp. 1–7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  216. C.-T. Lin, X.-Y. Sun, and A.-X. Lin, “Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study,” Renal Failure, vol. 38, no. 2, pp. 214–221, 2016. View at Publisher · View at Google Scholar · View at Scopus
  217. C. Cabrera, R. Artacho, and R. Giménez, “Beneficial effects of green tea—a review,” Journal of the American College of Nutrition, vol. 25, no. 2, pp. 79–99, 2006. View at Publisher · View at Google Scholar · View at Scopus
  218. C. S. Park, W. Kim, J. S. Woo et al., “Green tea consumption improves endothelial function but not circulating endothelial progenitor cells in patients with chronic renal failure,” International Journal of Cardiology, vol. 145, no. 2, pp. 261-262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  219. S. P. Hsu, M. S. Wu, C. C. Yang et al., “Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines,” The American Journal of Clinical Nutrition, vol. 86, no. 5, pp. 1539–1547, 2007. View at Publisher · View at Google Scholar
  220. S. Ellinger, N. Muller, P. Stehle, and G. Ulrich-Merzenich, “Consumption of green tea or green tea products: is there an evidence for antioxidant effects from controlled interventional studies?” Phytomedicine, vol. 18, no. 11, pp. 903–915, 2011. View at Publisher · View at Google Scholar · View at Scopus
  221. H. Bao and A. Peng, “The green tea polyphenol (—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease,” Journal of Translational Internal Medicine, vol. 4, no. 3, pp. 99–103, 2016. View at Publisher · View at Google Scholar
  222. A. Peng, T. Ye, D. Rakheja et al., “The green tea polyphenol (−)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis,” Kidney International, vol. 80, no. 6, pp. 601–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  223. T. Ye, J. Zhen, Y. du et al., “Green tea polyphenol (−)-epigallocatechin-3-gallate restores Nrf2 activity and ameliorates crescentic glomerulonephritis,” PLoS One, vol. 10, no. 3, article e0119543, 2015. View at Publisher · View at Google Scholar · View at Scopus
  224. P.-Y. Tsai, S.-M. Ka, J.-M. Chang et al., “Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation,” Free Radical Biology & Medicine, vol. 51, no. 3, pp. 744–754, 2011. View at Publisher · View at Google Scholar · View at Scopus
  225. N. Yamabe, T. Yokozawa, T. Oya, and M. Kim, “Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 1, pp. 228–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  226. P. Zhou, J. F. Yu, C. G. Zhao, F. X. Sui, X. Teng, and Y. B. Wu, “Therapeutic potential of EGCG on acute renal damage in a rat model of obstructive nephropathy,” Molecular Medicine Reports, vol. 7, no. 4, pp. 1096–1102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  227. L. A. Calo, U. Vertolli, P. A. Davis et al., “Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients,” Clinical Nutrition, vol. 33, no. 3, pp. 437–442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  228. G. Vogel, B. Tuchweber, W. Trost, and U. Mengs, “Protection by silibinin against Amanita phalloides intoxication in beagles,” Toxicology and Applied Pharmacology, vol. 73, no. 3, pp. 355–362, 1984. View at Publisher · View at Google Scholar · View at Scopus
  229. G. Vogel, R. Braatz, and U. Mengs, “On the nephrotoxicity of α-amanitin and the antagonistic effects of silymarin in rats,” Agents and Actions, vol. 9, no. 2, pp. 221–226, 1979. View at Publisher · View at Google Scholar · View at Scopus
  230. G. Floersheim, “Experimental basis for the therapy of Amanita phalloides poisoning,” Schweizerische Medizinische Wochenschrift, vol. 108, no. 6, pp. 185–197, 1978. View at Google Scholar
  231. C. Ninsontia, K. Pongjit, C. Chaotham, and P. Chanvorachote, “Silymarin selectively protects human renal cells from cisplatin-induced cell death,” Pharmaceutical Biology, vol. 49, no. 10, pp. 1082–1090, 2011. View at Publisher · View at Google Scholar · View at Scopus
  232. F. Shahbazi, S. Sadighi, S. Dashti-Khavidaki et al., “Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, placebo-controlled clinical trial,” Phytotherapy Research, vol. 29, no. 7, pp. 1046–1053, 2015. View at Publisher · View at Google Scholar · View at Scopus
  233. N. A. El-Shitany, S. El-Haggar, and K. El-Desoky, “Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats,” Food and Chemical Toxicology, vol. 46, no. 7, pp. 2422–2428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  234. P. F. Surai, “Silymarin as a natural antioxidant: an overview of the current evidence and perspectives,” Antioxidants, vol. 4, no. 1, pp. 204–247, 2015. View at Publisher · View at Google Scholar · View at Scopus
  235. S. Wenzel, H. Stolte, and M. Soose, “Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures,” Journal of Pharmacology and Experimental Therapeutics, vol. 279, no. 3, pp. 1520–1526, 1996. View at Google Scholar
  236. J. Sonnenbichler, F. Scalera, I. Sonnenbichler, and R. Weyhenmeyer, “Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells,” The Journal of Pharmacology and Experimental Therapeutics, vol. 290, no. 3, pp. 1375–1383, 1999. View at Google Scholar
  237. M. Täger, J. Dietzmann, U. Thiel, K. H. Neumann, and S. Ansorge, “Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin,” Free Radical Research, vol. 34, no. 2, pp. 137–151, 2001. View at Publisher · View at Google Scholar · View at Scopus
  238. J. Dietzmann, U. Thiel, S. Ansorge, K. H. Neumann, and M. Tüger, “Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy,” Free Radical Biology & Medicine, vol. 33, no. 10, pp. 1347–1354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  239. E. Homsi, S. M. de Brito, and P. Janino, “Silymarin exacerbates p53-mediated tubular apoptosis in glycerol-induced acute kidney injury in rats,” Renal Failure, vol. 32, no. 5, pp. 623–632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  240. H. Senturk, S. Kabay, G. Bayramoglu et al., “Silymarin attenuates the renal ischemia/reperfusion injury-induced morphological changes in the rat kidney,” World Journal of Urology, vol. 26, no. 4, pp. 401–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  241. F. Turgut, O. Bayrak, F. Catal et al., “Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats,” International Urology and Nephrology, vol. 40, no. 2, pp. 453–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  242. M. K. Fallahzadeh, B. Dormanesh, M. M. Sagheb et al., “Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial,” American Journal of Kidney Diseases, vol. 60, no. 6, pp. 896–903, 2012. View at Publisher · View at Google Scholar · View at Scopus
  243. J. Roozbeh, B. Shahriyari, M. Akmali et al., “Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis,” Renal Failure, vol. 33, no. 2, pp. 118–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  244. F. Nazemian, G. Karimi, M. Moatamedi, S. Charkazi, J. Shamsara, and A. H. Mohammadpour, “Effect of silymarin administration on TNF-α serum concentration in peritoneal dialysis patients,” Phytotherapy Research, vol. 24, no. 11, pp. 1654–1657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  245. O. Firuzi, S. Khajehrezaei, S. Ezzatzadegan, M. Nejati, K. A. Jahanshahi, and J. Roozbeh, “Effects of silymarin on biochemical and oxidative stress markers in end-stage renal disease patients undergoing peritoneal dialysis,” Hemodialysis International, vol. 20, no. 4, pp. 558–563, 2016. View at Publisher · View at Google Scholar · View at Scopus
  246. F. Galli, F. Canestrari, and G. Bellomo, “Pathophysiology of the oxidative stress and its implication in uremia and dialysis,” Contributions to Nephrology, vol. 127, pp. 1–31, 1999. View at Publisher · View at Google Scholar
  247. K. Khazim, D. Giustarini, R. Rossi et al., “Glutathione redox potential is low and glutathionylated and cysteinylated hemoglobin levels are elevated in maintenance hemodialysis patients,” Translational Research, vol. 162, no. 1, pp. 16–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  248. F. Galli, M. Piroddi, D. Bartolini et al., “Blood thiol status and erythrocyte glutathione-S-transferase in chronic kidney disease patients on treatment with frequent (daily) hemodialysis,” Free Radical Research, vol. 48, no. 3, pp. 273–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  249. O. I. Aruoma, B. Halliwell, B. M. Hoey, and J. Butler, “The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid,” Free Radical Biology & Medicine, vol. 6, no. 6, pp. 593–597, 1989. View at Publisher · View at Google Scholar · View at Scopus
  250. L. F. Drager, L. Andrade, J. F. Barros de Toledo, F. R. M. Laurindo, L. A. Machado Cesar, and A. C. Seguro, “Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury,” Nephrology, Dialysis, Transplantation, vol. 19, no. 7, pp. 1803–1807, 2004. View at Publisher · View at Google Scholar · View at Scopus
  251. V. Witko-Sarsat, V. Gausson, A. T. Nguyen et al., “AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients,” Kidney International, vol. 64, no. 1, pp. 82–91, 2003. View at Publisher · View at Google Scholar · View at Scopus
  252. A. Amore, M. Formica, F. Giacchino et al., “N-Acetylcysteine in hemodialysis diabetic patients resets the activation of NF-kB in lymphomonocytes to normal values,” Journal of Nephrology, vol. 26, no. 4, pp. 778–786, 2013. View at Publisher · View at Google Scholar · View at Scopus
  253. D. Giustarini, F. Galvagni, I. Dalle Donne et al., “N-Acetylcysteine ethyl ester as GSH enhancer in human primary endothelial cells: a comparative study with other drugs,” Free Radical Biology & Medicine, vol. 126, pp. 202–209, 2018. View at Publisher · View at Google Scholar · View at Scopus
  254. S. H. Sajwani and J. M. Bargman, “Novel ways to preserve the peritoneal membrane,” Advances in Peritoneal Dialysis, vol. 28, pp. 37–41, 2012. View at Google Scholar
  255. M. Nakayama, G. Izumi, Y. Nemoto et al., “Suppression of N(epsilon)-(carboxymethyl)lysine generation by the antioxidant N-acetylcysteine,” Peritoneal Dialysis International, vol. 19, no. 3, pp. 207–210, 1999. View at Google Scholar
  256. H. T. Kuo, J. J. Lee, H. H. Hsiao, H. W. Chen, and H. C. Chen, “N-Acetylcysteine prevents mitochondria from oxidative injury induced by conventional peritoneal dialysate in human peritoneal mesothelial cells,” American Journal of Nephrology, vol. 30, no. 3, pp. 179–185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  257. K. Y. Hung, S. Y. Liu, T. C. Yang, T. L. Liao, and S. H. Kao, “High-dialysate-glucose-induced oxidative stress and mitochondrial-mediated apoptosis in human peritoneal mesothelial cells,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 642793, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  258. S. Cuzzocrea, E. Mazzon, G. Costantino, I. Serraino, A. De Sarro, and A. P. Caputi, “Effects of n-acetylcysteine in a rat model of ischemia and reperfusion injury,” Cardiovascular Research, vol. 47, no. 3, pp. 537–548, 2000. View at Publisher · View at Google Scholar · View at Scopus
  259. J. DiMari, J. Megyesi, N. Udvarhelyi, P. Price, R. Davis, and R. Safirstein, “N-Acetyl cysteine ameliorates ischemic renal failure,” American Journal of Physiology-Renal Physiology, vol. 272, no. 3, pp. F292–F298, 1997. View at Publisher · View at Google Scholar
  260. J. Luo, T. Tsuji, H. Yasuda, Y. Sun, Y. Fujigaki, and A. Hishida, “The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats,” Nephrology, Dialysis, Transplantation, vol. 23, no. 7, pp. 2198–2205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  261. O. Ivanovski, D. Szumilak, T. Nguyen-Khoa et al., “The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice,” Kidney International, vol. 67, no. 6, pp. 2288–2294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  262. D. Bozkurt, E. Hur, B. Ulkuden et al., “Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis?” Peritoneal Dialysis International, vol. 29, Supplement 2, pp. S202–S205, 2009. View at Google Scholar
  263. H. Noh, J. S. Kim, K. H. Han et al., “Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane,” Kidney International, vol. 69, no. 11, pp. 2022–2028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  264. H. Trimarchi, M. R. Mongitore, P. Baglioni et al., “N-Acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients - a pilot study,” Clinical Nephrology, vol. 59, no. 06, pp. 441–446, 2003. View at Publisher · View at Google Scholar · View at Scopus
  265. M. Thaha, Widodo, W. Pranawa, M. Yogiantoro, and Y. Tomino, “Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients,” Clinical Nephrology, vol. 69, no. 1, pp. 24–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  266. S. P. Hsu, C. K. Chiang, S. Y. Yang, and C. T. Chien, “N-Acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients,” Nephron Clinical Practice, vol. 116, no. 3, pp. c207–c216, 2010. View at Publisher · View at Google Scholar · View at Scopus
  267. I. Giannikouris, “The effect of N-acetylcysteine on oxidative serum biomarkers of hemodialysis patients,” Hippokratia, vol. 19, no. 2, pp. 131–135, 2015. View at Google Scholar
  268. F. Saddadi, S. Alatab, F. Pasha, M. R. Ganji, and T. Soleimanian, “The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis,” Saudi Journal of Kidney Diseases and Transplantation, vol. 25, no. 1, pp. 66–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  269. H. Shahbazian, S. Shayanpour, and A. Ghorbani, “Evaluation of administration of oral N-acetylcysteine to reduce oxidative stress in chronic hemodialysis patients: a double-blind, randomized, controlled clinical trial,” Saudi Journal of Kidney Diseases and Transplantation, vol. 27, no. 1, pp. 88–93, 2016. View at Publisher · View at Google Scholar · View at Scopus
  270. A. Modarresi, S. Ziaie, J. Salamzadeh et al., “Study of the effects of N-acetylcysteine on oxidative stress status of patients on maintenance-hemodialysis undergoing cadaveric kidney transplantation,” Iranian Journal of Pharmaceutical Research, vol. 16, no. 4, pp. 1631–1638, 2017. View at Google Scholar
  271. A. N. Friedman, A. G. Bostom, P. Laliberty, J. Selhub, and D. Shemin, “The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study,” American Journal of Kidney Diseases, vol. 41, no. 2, pp. 442–446, 2003. View at Publisher · View at Google Scholar · View at Scopus
  272. A. G. Bostom, D. Shemin, D. Yoburn, D. H. Fisher, M. R. Nadeau, and J. Selhub, “Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients,” Atherosclerosis, vol. 120, no. 1-2, pp. 241–244, 1996. View at Publisher · View at Google Scholar · View at Scopus
  273. A. Scholze, C. Rinder, J. Beige, R. Riezler, W. Zidek, and M. Tepel, “Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure,” Circulation, vol. 109, no. 3, pp. 369–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  274. J.-P. Tsai, F.-L. Yang, C.-H. Wang, T.-C. Fang, R.-P. Lee, and B.-G. Hsu, “Effect of intravenous N-acetylcysteine on plasma total homocysteine and inflammatory cytokines during high flux hemodialysis,” Tzu Chi Medical Journal, vol. 22, no. 2, pp. 90–95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  275. M. Thaha, M. Yogiantoro, and Y. Tomino, “Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease,” Clinical Drug Investigation, vol. 26, no. 4, pp. 195–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  276. G. Swarnalatha, R. Ram, P. Neela, M. U. Naidu, and K. V. Dakshina Murty, “Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress,” Saudi Journal of Kidney Diseases and Transplantation, vol. 21, no. 5, pp. 852–858, 2010. View at Google Scholar
  277. N. Garcia-Fernandez, A. Echeverria, A. Sanchez-Ibarrola, J. A. Paramo, and I. Coma-Canella, “Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis,” Nephrology, vol. 15, no. 2, pp. 178–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  278. B. Purwanto and D. H. Prasetyo, “Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients,” Acta Medica Indonesiana, vol. 44, no. 2, pp. 140–144, 2012. View at Google Scholar
  279. J. M. Bargman, K. E. Thorpe, D. N. Churchill, and Group CPDS, “Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study,” Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2158–2162, 2001. View at Google Scholar
  280. R. Furuya, H. Kumagai, M. Odamaki, M. Takahashi, A. Miyaki, and A. Hishida, “Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients,” Nephron Clinical Practice, vol. 112, no. 4, pp. c255–c261, 2009. View at Publisher · View at Google Scholar · View at Scopus
  281. S. Ignace, D. Fouque, W. Arkouche, J. P. Steghens, and F. Guebre-Egziabher, “Preserved residual renal function is associated with lower oxidative stress in peritoneal dialysis patients,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1685–1689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  282. L. Feldman, M. Shani, S. Efrati et al., “N-Acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study,” Peritoneal Dialysis International, vol. 31, no. 5, pp. 545–550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  283. L. Feldman, M. Shani, I. Sinuani, I. Beberashvili, and J. Weissgarten, “N-Acetylcysteine may improve residual renal function in hemodialysis patients: a pilot study,” Hemodialysis International, vol. 16, no. 4, pp. 512–516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  284. F. Ahmadi, M. Abbaszadeh, E. Razeghi et al., “Effectiveness of N-acetylcysteine for preserving residual renal function in patients undergoing maintenance hemodialysis: multicenter randomized clinical trial,” Clinical and Experimental Nephrology, vol. 21, no. 2, pp. 342–349, 2017. View at Publisher · View at Google Scholar · View at Scopus
  285. G. Sahin, A. U. Yalcin, and N. Akcar, “Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients,” Blood Purification, vol. 25, no. 4, pp. 309–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  286. M. Tepel, M. van der Giet, M. Statz, J. Jankowski, and W. Zidek, “The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial,” Circulation, vol. 107, no. 7, pp. 992–995, 2003. View at Publisher · View at Google Scholar · View at Scopus